This coastal gem is America's hottest's ZIP code
A newcomer to the annual Realtor.com® Hottest ZIP Codes in the U.S. is 01915, in Beverly, MA.
Advertisement
Beverly is located a little over 20 miles northeast of Boston, along the Atlantic coast. Home to more than 43,000 residents, Beverly offers an appealing combination of relative affordability, small-town charm, and easy proximity to a bustling economic hub.
The hottest ZIP code rankings from Realtor.com take into account two aspects of the housing market: market demand, as measured by unique viewers per property on the website, and the pace of the market as measured by the number of days a listing remains active.
The hottest areas are those that have the most unique viewers per listed property and fast-selling homes—a sign of limited supply.
This year, the off-the-radar town emerged as the nation's most desirable housing market. Here is everything you need to know about what makes Beverly a top destination for savvy homebuyers.
Beverly offers quality of life and job opportunities
Advertisement
4 A newcomer to the annual Realtor.com® Hottest ZIP Codes in the U.S. is 01915, in Beverly, MA.
Wangkun Jia – stock.adobe.com
Located within the greater Boston metro area, Beverly combines laid-back coastal living with relative affordability, attracting buyers looking to balance quality of life with easy access to well-paying jobs in the big city.
Despite its small size, Beverly is home to major employers, including CVS Health, the U.S. Postal Service, and DoorDash.
Additionally, the Cummings Center, a thriving mixed-use development in Beverly, houses about 600 different businesses, among them AllClear Healthcare and Aetna Medicare Solutions.
Advertisement
With its commuter rail station offering direct trains to Boston, Beverly represents an attractive option for city workers seeking small-town charm and urban convenience.
'Beverly is a great city to live in,' Adeline Matton, a real estate agent and broker with Aluxety Realty, tells Realtor.com. 'First of all, it's so scenic. It's an oceanside city. We have the harbor, we have yacht clubs, beautiful beaches, beautiful parks, beautiful greenery, and downtown is thriving.'
Matton, who lived in Beverly for 25 years and raised her family there, says it is no surprise to her that more people are drawn to the area.
'It really has so much to offer, and it's not surprising that it would make the top ZIP,' the veteran agent notes.
Beverly homes are in high demand
Advertisement
4 Despite its small size, Beverly is home to major employers, including CVS Health, the U.S. Postal Service, and DoorDash.
Wangkun Jia – stock.adobe.com
For-sale homes in Beverly waited for a buyer just 16 days in June, received nearly five times more listing views on Realtor.com than the national average between January and June 2025, and sold for a median price that, though elevated, was still a downright bargain compared with Boston and some of its other suburbs.
Notably, the typical home in the U.S. in June 2025 lingered on the market for 53 days—more than three times longer than in Beverly.
This underscores the persistent inventory shortages across the Northeast, where buyer demand routinely outstrips supply.
Perhaps unsurprisingly, more than 62% of views directed at listings in Beverly came from within the Boston metro.
When looking at out-of-market interest, New York City dominated, with Big Apple buyers accounting for more than 11% of Beverly's listing traffic.
'These shoppers are increasingly seeking out ZIPs with better value just outside of expensive urban cores,' says Realtor.com Chief Economist Danielle Hale.
What's the price of a home in Beverly?
4 Notably, the typical home in the U.S. in June 2025 lingered on the market for 53 days—more than three times longer than in Beverly.
Wangkun Jia – stock.adobe.com
Advertisement
As of June, the median list price in Beverly climbed to $719,000, nearly $280,000 higher than the national median for the month. The average price in Beverly from January through June was $746,000.
But at the same time, the typical home in Beverly remained roughly 18% below the Boston metro average, which came in at $855,000 in June, landing Beantown among the five most expensive metros in the country.
This year's hottest ZIP codes, led by Beverly, tell a broader story about how homebuyers are adapting to stubbornly high mortgage rates and affordability challenges, according to Hale.
What the latest ranking shows, according to the chief economist, is that buyers are increasingly focusing on relative value, not just low price tags. This explains why they are drawn to ZIP codes where properties are priced below local metro medians, even if above the national norm.
Advertisement
'These locations represent a sweet spot for shoppers who want suburban amenities and proximity to jobs without paying top-tier metro premiums,' adds Hale.
Matton, the real estate agent, points out that Beverly's slightly greater distance from Boston, compared with pricier suburbs like Newton, Arlington, and Watertown, helps keep the local housing market more affordable.
'Beverly, being a little bit outside of the city, a little bit farther north … does have lower prices than a lot of those cities,' she says. 'We are seeing a lot of people maybe selling a smaller house in one of those suburbs and heading north to Beverly.'
According to the latest available data, the median list price per square foot in Beverly was nearly 3% lower than in Boston. In other words, buyers in the suburban city could purchase a bigger home for less money.
What else makes Beverly stand out?
Advertisement
4 As of June, the median list price in Beverly climbed to $719,000, nearly $280,000 higher than the national median for the month.
Wangkun Jia – stock.adobe.com
Named after a city in England, Beverly was first settled in 1626 and was initially part of Salem. In the mid-17th century, it was incorporated as its own town in the Massachusetts Bay Colony.
Beverly is recognized as the 'Birthplace of the American Navy,' having been the base of the Continental Navy's first warship, the schooner Hannah, which was commissioned by President George Washington.
Beverly's other claim to historic fame is that the first cotton mill in the U.S. was built there in the late 1780s. Washington visited the site two years later and came away impressed with the technology.
Advertisement
Some top Beverly landmarks include the historic Cabot Theatre, the John Cabot House, and Lynch Park.
These days, Beverly offers residents a mix of livability, more space, and greater affordability relative to Boston.
Matton says Beverly appeals to buyers with its numerous amenities, including a highly rated school system, standout sports programs, and a wide array of shops and restaurants.
'The market's always been strong there, and it's continued to grow,' she adds. 'The city offers so much to people moving in there.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
Eli Lilly earnings are coming Thursday. Here's what top analysts expect
Many on Wall Street expect that Novo Nordisk 's loss has been Eli Lilly 's gain, and this will be good news for the Zepbound maker's second-quarter results. Novo Nordisk's stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and Wegovy for obesity. The company has said its business has been hurt by competition from compounding pharmacies, which are making knock-off versions of its semaglutide, the active ingredient in both brands. This prompted Novo to cut its annual forecast and oust its CEO. Lilly's business appears to be holding up much better, according to analysts. They anticipate the proof will be in the quarterly results and outlook. What's more, several analysts expect other catalysts, including next-generation drugs, to help propel Lilly shares higher. 'Potential materiality' So far this year, Lilly's stock has logged a roughly 3% decline, underperforming the market. However, catalysts could come as soon as Thursday, analysts say. "We note that LLY's upcoming 2Q call is scheduled for 8:30am ET on Aug 7th, as opposed the company's standard 10am ET time slot for earnings calls after the market opens, suggesting potential materiality via topline trial results alongside earnings," Goldman Sachs analyst Asad Haider wrote in a July 28 research note. He said the report is "the most highly anticipated near-term event" across his pharmaceutical coverage. In addition to the financial outlook, investors are eager to hear more about orforglipron , the company's experimental GLP-1 pill. In June, at the American Diabetes Association conference, Lilly revealed the drug helped patients with type 2 diabetes in a late-stage trial lose weight without serious side effects . The readout of the phase 3 data for patients with obesity should be released soon. Wegovy's 'favored status' Analysts are also eager to hear management's thoughts on CVS Health 's policy of giving favored status to Wegovy over Lilly's Zepbound. The policy went into effect in July and means CVS Health's pharmacy benefit manager Caremark will prioritize Wegovy on its list of covered drugs. It has the potential to be a headwind for Lilly. However, patients may seek exemptions and remain on the weight loss drug or pay out of pocket on their own or via Lilly Direct, the company's direct-to-consumer website. Also, there is the possibility Lilly will strike a deal and get back on CVS Caremark's list of covered medications, analysts said. According to Bernstein analyst Courtney Breen, the first few weeks of the switch showed that patients changing from Zepbound to Wegovy was eclipsed by the number of patients starting the drug with a new prescription. On average, analysts surveyed by LSEG expect Lilly will earn $5.57 per share in the second quarter on revenue of $14.71 billion. If Lilly hits that revenue estimate, it will have achieved 30% growth year over year. Here's what else they're saying ahead of the report. LLY YTD mountain Eli Lilly shares year to date. Citigroup: Buy rating, $1,190 price target Citi analyst Geoff Meacham said Lilly remains one of its favorite stocks, and he placed a 90-day catalyst watch on it on July 30. His $1,190 price target implies 55% upside from Tuesday's close. "GLP-1 script data from IQVIA give us continued confidence in achievability of Lilly's 2025 revenue guidance ($58B-$61B). Notably, Zepbound scripts remain robust (+45% q/q) and overall share increased to 65.5%, representing a gain of ~600bps in market share. We think this is particularly noteworthy given vials from LillyDirect now represent ~20% of TRx [total prescriptions] and highlight increasing potential for a consumer angle in GLP-1 sales … driving uptake going forward (2Q25e $3.1B; +$99M vs. BBG cons). [Type 2 diabetes drug] Mounjaro scripts rose 16.3% q/q and now captures 42.2% share (2Q25e $4.5B; +$18M vs. cons); though slower growth than Zepbound, this is expected given the more entrenched nature of the type 2 diabetes market. … Top of mind for investors will be orforglipron's phase 3 ATTAIN readouts for obesity (Jul/Aug). Weight loss of 12-15% is the efficacy bar and continuation of a squeaky-clean safety profile that we saw at ADA for ACHIEVE … will be paramount." Morgan Stanley: Overweight, $1,135 In early July, Morgan Stanley analyst Terence Flynn tweaked his price target, increasing it to $1,135 from $1,133. The target suggests 48% upside. "In our view the magnitude of potential Mounjaro+Zepbound 2Q beat will dictate how LLY handles 2025 revenue guidance of $58-$61bn (MS $62.3bn vs. Cons $59.8bn), but we expect a raise of the low end at a minimum. LLY could also release Orfor Ph3 obesity and/or SURPASS-CVOT data in conjunction with earnings. … Interim Ph3 data for LLY's Kisunla in preclinical Alzheimer's (potentially later this year) could be a de-risking event for treating earlier in the disease course and expand the opportunity for the category, as well as provide lateral read-through to BIIB/Eisai's Leqembi (where Ph3 is also ongoing)" Bernstein: Outperform, $1,100 Bernstein, Wells Fargo and JPMorgan all have a $1,100 price target for Lilly's stock, which suggests it could rise nearly 44% from Tuesday's close. "We again see the potential for a meet or beat … , driven by Mounjaro & Zepbound performance. Given most of the street follow scripts closely in the US, the upside here arises from additional unexpected pricing (rebate adjustments), underreporting in IQVIA (a possibility), and ex-US performance (due to lower visibility). … Despite the potential for a top-line beat (we see potential for modest 1.2% beat above consensus at 14.6B), we don't anticipate LLY will be rushing to increase guidance, given last years back half challenges and the uncertainty for Q3 that remains on CVS caremark (although initial signs look strong)." Wells Fargo: Overweight, $1,100 "NVO lowering their guidance on Ozempic and Wegovy headwinds could be limited to NVO itself, as they cite continued compounding, competition, and slower market expansion. We believe LLY guidance can be raised on strong underlying trends. … Therefore, we would be buyers of LLY on the weakness since we expect a strong 2Q and a catalyst-rich 2H'25." JPMorgan: Overweight, $1,100 "Overall, we are expecting a solid 2Q for LLY with upside to Mounjaro/Zepbound (based on strong TRx growth trends), and we estimate total sales in the qtr of $14.8bn (+$370mm vs cons). On the EPS line, we are slightly below consensus ($5.49, -$0.06) as we expect a continued opex ramp to support a growing late stage pipeline and [direct-to consumer] initiatives. Looking forward, we expect some moderation in Zepbound growth as the CVS formulary change takes effect on July 1 but expect the product to still grow TRx in 3Q and accelerate in 4Q. And for the year, our estimates are near the high end of the company's 2025 guidance on both topline ($60.8bn sales, +$1.3bn vs cons) and the bottomline ($22.09 EPS, +$0.07 vs cons) and we would not be surprised to see LLY raise guidance at some point in 2025 (although the company may take a more conservative approach on the timing/magnitude of the increases given 2024 guidance dynamics)." Goldman Sachs: Buy, $883 Haider's $883 price target is about 15% above where Lilly shares closed on Tuesday. " … we expect another revenue beat, driven by an [foreign exchange] tailwind and strong TRx growth for Zepbound/Mounjaro where our and consensus estimates have tracked higher into the print. ... Into the 2Q earnings call, we also note significant investor discussion on the magnitude of potential upward pressure on the company's FY25 revenue guidance where we expect management could tighten the range of $58-$61bn for the year by bumping up the low-end (based on 1H trends, GS/consensus estimates are $60bn/$60.6bn for 2025). These trends are now well-understood with investor focus higher on trying to triangulate the impact to 3Q25 sales for Zepbound/Mounjaro from the CVS formulary change in favor of Novo that took effect on July 1st."
Business Wire
3 hours ago
- Business Wire
ASP Introduces BIOTRACE™ Instant Read Steam System, Delivering Sterility Assurance in Just Seven Seconds
IRVINE, Calif.--(BUSINESS WIRE)--Advanced Sterilization Products (ASP), a global leader in infection prevention and sterilization solutions, is announcing the launch of the BIOTRACE™ Instant Read Steam System, the fastest FDA-cleared steam biological indicator system available in the U.S. Designed with sterile processing departments (SPDs) in mind, the new system delivers a readout in just seven seconds, drastically reducing wait time, minimizing errors, and enhancing clinical workflow efficiency. Current standard biological indicator systems can take 20 minutes or longer to generate a readout. BIOTRACE Instant Read Steam System changes the paradigm by offering SPDs the ability to verify sterilization results nearly immediately, which allows for faster decision-making, improved throughput, and reduced operational strain. In a hospital environment where every minute counts and every load matters, this technology enables confident, real-time transitions from sterilization to documentation. 'The launch of BIOTRACE Instant Read Steam System represents a significant advancement in our ability to deliver fast, actionable sterility data to frontline staff,' said Dr. Ivan Salgo, Vice President and Chief Medical and Scientific Officer at ASP. 'By reducing the readout time to just seconds, we're addressing a long-standing bottleneck that often impacts both productivity and peace of mind. This system supports SPDs not only in meeting compliance standards, but in exceeding them, with confidence.' Developed with advanced fluorescence detection, BIOTRACE Instant Read Steam System streamlines routine monitoring of steam sterilization cycles without compromising accuracy. The compact reader accommodates two simultaneous test positions, records the last 50 results, and connects seamlessly to digital infrastructure via USB, Wi-Fi, or Bluetooth®. Integration with the BIOTRACE™ Assist App and SM Cloud™ Web Application enables secure cloud storage, enhanced traceability, and automated reporting for hospital instrument tracking systems including CensiTrac™ and other major ITS software solutions. 'ASP is proud to lead the charge in redefining sterility assurance,' said Chad Rohrer, Global President of ASP. 'This is a leap forward in our commitment to help hospitals do more with less, supporting frontline staff with technology that empowers their work. The introduction of BIOTRACE Instant Read Steam System reinforces our role as a trusted partner in innovation for infection prevention, while elevating the standards of care and operational excellence.' A recent usability study confirmed that throughput and staffing remain top concerns in SPDs nationwide. Respondents cited a strong willingness to invest in time-saving technology, recognizing the value of immediate sterilization verification in high-pressure clinical environments. Hospitals and health systems can request demos and evaluation kits by contacting their ASP representative. About Advanced Sterilization Products (ASP) Advanced Sterilization Products (ASP), a Fortive company, is a global leader in infection prevention dedicated to safeguarding patients during their most critical moments. With a proven history of pioneering low-temperature sterilization and sterility assurance solutions, ASP delivers innovative technologies designed to raise the standard of care across healthcare settings. From terminal sterilization with hydrogen peroxide gas plasma to advanced steam monitoring tools, ASP supports healthcare facilities worldwide in improving efficiency, compliance, and patient safety. For more information, visit Advanced Sterilization Products (ASP) and Censis Technologies are subsidiaries of Fortive Corporation. CensiTrac™ software is a product of Censis Technologies. DISCLOSURE: The third-party trademarks used herein are the properties of their respective owners.
Yahoo
3 hours ago
- Yahoo
Allegiant Again Tops USA TODAY's Readers' Choice Awards for Best Airline Credit Card and Best Frequent Flyer Program
Allegiant's Allways Rewards Visa® and Allways Rewards Program Ranks No. 1 for Second Consecutive Year LAS VEGAS, Aug. 6, 2025 /PRNewswire/ -- Allegiant (NASDAQ: ALGT) has once again claimed top honors in USA TODAY's 10Best 2025 Readers' Choice Awards, earning the No. 1 spot in both Best Airline Credit Card and Best Frequent Flyer Program categories. This marks the second consecutive year Allegiant has led both categories, reinforcing its commitment to delivering exceptional value and rewarding loyalty among leisure travelers. The Allways Rewards Visa® card continues its winning streak, now recognized as the best airline credit card for the seventh year in a row. With generous travel rewards, no blackout dates, and exclusive access to memorable experiences, the card remains a favorite among travel enthusiasts. "We're honored to be recognized again by USA TODAY readers for our credit card and frequent flyer programs," said Drew Wells, Allegiant's chief commercial officer. "These awards reflect the voice of our customers, and we're proud to offer loyalty programs that are transparent, inclusive, and designed to meet the needs of both occasional and frequent travelers." The Allways Rewards frequent flyer program continues to stand out for its simplicity and flexibility. As the first airline loyalty program designed specifically for leisure travelers, it allows members to earn and redeem points based on dollars spent rather than miles flown. "When we built the program, our goal was to ensure customers could use their points easily and receive immediate benefits," added Wells. "We intentionally moved away from traditional miles-based loyalty models, which primarily serve high-mileage business travelers." Also, unlike most travel reward programs, points are awarded to the buyer rather than to an individual traveler. This means Allways members receive full credit for booking travel for others, such as family members. USA TODAY's 10Best Readers' Choice Awards celebrate excellence across travel, food, entertainment, and more. Nominees are selected by a panel of experts and editors, and winners are determined by public vote. Allegiant's continued recognition underscores its dedication to customer satisfaction, value, and innovation in travel rewards. For more information about the 10Best Readers' Choice Awards and to view the full list of winners, click here. Allegiant – Together We Fly™ Las Vegas-based Allegiant (NASDAQ: ALGT) is an integrated travel company with an airline at its heart, focused on connecting customers with the people, places and experiences that matter most. Since 1999, Allegiant Air has linked travelers in small-to-medium cities to world-class vacation destinations with all-nonstop flights and industry-low average fares. Today, Allegiant serves communities across the nation, with base airfares less than half the cost of the average domestic roundtrip ticket. For more information, visit us at Media information, including photos, is available at Media Contact Phone: 702-800-2020Email: mediarelations@ View original content to download multimedia: SOURCE Allegiant Travel Company Melden Sie sich an, um Ihr Portfolio aufzurufen.
